



SEQUENCE LISTING

<110> Rybczynski, Philip
et al.

<120> BIOLOGICALLY ACTIVE 4H-BENZO[1,4]OXAZIN-3-ONES

<130> pm431, patin2.1

<140>

<141>

<160> 15

<170> PatentIn Ver. 2.1

<210> 1

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 1

cattttgtga gttttctagg attattcttt tctcttgaa agaaaagt

47

<210> 2

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 2

atgttaggtt tggccatgcc tttctcttgg aaagaaaagt

39

<210> 3

<211> 41

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 3

cctctcgttt tctctttatg gttttctctt ggaaagaaag t

41

<210> 4

<211> 47

<212> DNA

<213> Artificial Sequence

COPY OF PAPERS
ORIGINALLY FILED

<220>
<223> Description of Artificial Sequence: primer

<400> 4
gcttatgctc tctcataaac tctcggtt tctcttgaa agaaagt 47

<210> 5
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 5
ccaggtacct acaaaagcat cacattnagg cataggaccc gtgtct 46

<210> 6
<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 6
gcccactcct acttctttca tataatcatt taggcattagg acccgtgtct 50

<210> 7
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 7
agccactttc ctggtggcaa attaggcatt aggaccgtg tct 43

<210> 8
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 8
catccccatt cacactgatg atctttaggc ataggacccg tgtct 45

<210> 9
<211> 48

<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 9
gtaccaggac acccccatct aaggtttta ggcataaggac ccgtgtct 48

<210> 10
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 10
ggttgatttt ccatcccatt tctgcacatt ttaggcata gaccgcgtc t 51

<210> 11
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 11
gcattccacc accagttat catttaggc ataggacccg tgtct 45

<210> 12
<211> 52
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 12
gcgaacttca gtccaggtca acgtcccttg ttaggcata ggaccgcgtc ct 52

<210> 13
<211> 48
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 13
tccccacagaa tggttagag ttcaatttta ggcataaggac ccgtgtct 48

<210> 14
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 14
aaaacaacaa tatcttttg aacaatata ttaggcata gaccgggtgc t 51

<210> 15
<211> 26
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: primer

<400> 15
tcaaagttt cactggagac aagttt 26



UNITED STATES PATENT AND TRADEMARK OFFICE

OCT 17 2002
MAY 09 2002
PATENT & TRADEMARK OFFICE

COPIES
ORIGINALLY FILED

Page 1 of 1

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/990,461	11/21/2001	Thomas P. Burris	ORT-1527

CONFIRMATION NO. 4152

000027777
AUDLEY A. CIAMPORCERO JR.
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933-7003

FORMALITIES LETTER

RECEIVED

2000000007703933*

MAR 28 2002

Date Mailed: 03/25/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES


Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d). Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

A copy of this notice **MUST** be returned with the reply.


Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY